Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland.

Abstract

BACKGROUND:

The coronavirus disease 19 (COVID-19) recently became one of the leading causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may influence the prognosis of patients with COVID-19.

AIMS:

We analyzed the impact of CVD and the use of cardiovascular drugs on the in-hospital course and mortality of patients with COVID-19.

METHODS:

We retrospectively studied data for consecutive patients admitted to our hospital, with COVID-19 between March 6th and October 15th, 2020.

RESULTS:

1729 patients (median interquartile range age 63 [50-75] years; women 48.8%) were included. Overall, in-hospital mortality was 12.9%. The most prevalent CVD was arterial hypertension (56.1%), followed by hyperlipidemia (27.4%), diabetes mellitus (DM) (25.7%), coronary artery disease (16.8%), heart failure (HF) (10.3%), atrial fibrillation (13.5%), and stroke (8%). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) were used in 25.0% of patients, β-blockers in 40.7%, statins in 15.6%, and antiplatelet therapy in 19.9%. Age over 65 years (odds ratio [OR], 6.4; 95% CI, 4.3-9.6), male sex (OR, 1.4; 95% CI, 1.1-2.0), pre-existing DM (OR, 1.5; 95% CI, 1.1-2.1), and HF (OR, 2.3; 95% CI, 1.5-3.5) were independent predictors of in-hospital death, whereas treatment with ACEIs/ARBs (OR, 0.4; 95% CI, 0.3-0.6), β-blockers (OR, 0.6; 95% CI, 0.4-0.9), statins (OR, 0.5; 95% CI, 0.3-0.8), or antiplatelet therapy (OR, 0.6; 95% CI: 0.4-0.9) was associated with lower risk of death.

CONCLUSIONS:

Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.

• Authors: Michał Terlecki, Wiktoria Wojciechowska, Marek Klocek, Agnieszka Olszanecka, Katarzyna Stolarz-Skrzypek, Tomasz Grodzicki, Maciej Małecki, Barbara Katra, Aleksander Garlicki, Monika Bociąga-Jasik, Krzysztof Sładek, Andrzej Matyja, Jerzy Wordliczek, Agnieszka Słowik, Tomasz Mach, Katarzyna Krzanowska, Marcin Krzanowski, Paweł Stręk, Piotr Chłosta, Piotr Hydzik, Mariusz Korkosz, Tadeusz Popiela, Maciej Pilecki, Artur Gądek, Marek Rajzer
• Journal: Kardiologia polska (Kardiol Pol) Vol. 79 Issue 7-8 Pg. 773-780 ( 2021) ISSN: 1897-4279 [Electronic] Poland
• PMID: 33926173 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Cardiovascular Agents

Topics

• Aged
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• COVID-19
• Cardiovascular Agents
• Cardiovascular Diseases (drug therapy, epidemiology)
• Female
• Hospital Mortality
• Hospitals
• Humans
• Hypertension
• Male
• Middle Aged
• Poland (epidemiology)
• Registries
• Retrospective Studies
• SARS-CoV-2